ArticleBMJ paediatrics open2026
Limited willingness to switch from intravenous to subcutaneous treatment in paediatric inflammatory bowel disease.
Article in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRecent advances in inflammatory bowel disease (IBD) therapies have provided patients with a variety of medications administered via different routes. We aimed to assess parental preferences regarding medication administration routes and to identify the factors influencing these preferences.
designThis cross-sectional study surveyed the parents of children with IBD using a comprehensive questionnaire focusing on treatment experiences, preferences and attitudes towards switching from intravenous (IV) to subcutaneous (SC) administration. The questionnaire explored various regimens, including oral pills, SC injections at different intervals and IV infusions.
resultsOf the 147 participants, daily oral administration and SC administration every 8 weeks were the most preferred options. IV and SC administration every 2 weeks was less favoured. Prior treatment experience significantly influenced the parents' preferences regarding administration routes and schedules. Despite new options allowing for SC administration, 67% of parents preferred not to switch from IV, citing concerns about self-injection, desire for nurse presence and longer intervals between infusions. No significant correlation was found between treatment preferences and disease-related factors such as disease type or activity.
conclusionThese findings highlight the complexities of transitioning paediatric patients with IBD to alternative treatment methods, emphasising the importance of individualised care and parental perspectives in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.